AUPH Aurinia Pharmaceuticals Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1600620 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.0%
TTM net income YoY303.7%
TTM EPS YoY308.9%
Revenue 3-yr CAGR26.5%
Net income 3-yr CAGR—
Margins
Gross margin90.6%
Operating margin48.6%
Net margin97.7%
FCF margin—
EBITDA margin54.6%
Returns
ROE61.4%
ROA46.4%
ROIC (approx.)34.6%
Asset turnover0.48x
Leverage & solvency
Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage40.36x
Cash quality & payout
Operating cash flow / net income0.56x
Accruals ratio20.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $283.06M | $235.13M | $175.51M | $134.03M | $45.60M |
| Cost of revenue | $32.66M | $28.25M | $14.15M | $5.66M | $1.09M |
| Gross profit | $250.39M | $206.88M | $161.37M | $128.37M | $44.51M |
| R&D expense | $32.51M | $20.79M | $49.64M | $44.99M | $51.14M |
| SG&A expense | $101.79M | $172.03M | $195.04M | $196.37M | $173.50M |
| Operating income | $104.91M | -$4.69M | -$91.69M | -$111.47M | -$180.74M |
| Interest expense | $4.33M | $4.83M | $2.77M | $0 | $0 |
| Pretax income | $114.16M | $7.45M | -$77.47M | -$106.35M | -$180.21M |
| Income tax | -$173.04M | $1.70M | $551,000 | $1.83M | $760,000 |
| Net income | $287.20M | $5.75M | -$78.02M | -$108.18M | -$180.97M |
| EBITDA | $124.36M | $14.76M | -$80.04M | -$108.76M | -$177.97M |
| EPS (basic) | 2.14 | 0.04 | -0.54 | -0.76 | -1.40 |
| EPS (diluted) | 2.07 | 0.04 | -0.54 | -0.76 | -1.40 |
| Weighted avg. shares (diluted) | 138.70M | 146.19M | 143.24M | 141.91M | 129.37M |
| Balance sheet | |||||
| Cash & equivalents | $80.21M | $83.43M | $48.76M | $94.17M | $231.90M |
| Inventory | $45.69M | $39.23M | $39.70M | $24.75M | $19.33M |
| Current assets | $491.97M | $446.60M | $424.80M | $442.54M | $513.32M |
| PP&E, net | $2.11M | $2.73M | $3.35M | $3.65M | $4.42M |
| Intangibles | $3.76M | $4.36M | $4.98M | $6.42M | $8.40M |
| Total assets | $751.59M | $550.64M | $548.06M | $470.86M | $543.37M |
| Current liabilities | $93.72M | $97.76M | $77.19M | $46.11M | $40.65M |
| Total liabilities | $170.26M | $173.17M | $170.11M | $65.42M | $64.28M |
| Shareholders' equity | $581.33M | $377.48M | $377.95M | $405.44M | $479.09M |
| Shares outstanding | 132.32M | 140.88M | 143.83M | 142.27M | 141.60M |
| Cash flow statement | |||||
| Operating cash flow | $135.66M | $44.39M | -$33.46M | -$79.53M | -$157.69M |
| Investing cash flow | -$32.77M | $39.26M | -$6.71M | -$60.63M | -$103.87M |
| Financing cash flow | -$106.11M | -$49.09M | -$5.13M | $2.43M | $221.11M |
| Depreciation & amortization | $19.45M | $19.45M | $11.65M | $2.71M | $2.76M |
| Stock-based compensation | $14.68M | $31.60M | $45.31M | $32.30M | $31.24M |
| Share buybacks | $98.16M | $40.24M | $0 | $0 | — |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.